Мақола

POS-320 EFFECTIVENESS AND SAFETY OF RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH OBESITY, TYPE TWO DIABETES AND CKD

Sherzod AbdullaevRepublican Scientific and Practical Medical Center of Nephrology and Kidney Transplantation, Immunogenetics, Tashkent, UzbekistanRanokhon IgamberdievaTashkent pediatric medical institute, Internal medicine, Tashkent, Uzbekistan

Kidney International Reportsjournal2022en

ABI

Аннотация

We aimed to evaluate the clinical characteristics and outcomes of rivaroxaban and warfarin in patients with nonvalvular atrial fibrillation (NVAF) and concurrent obesity, type two diabetes (T2D) and chronic kidney disease (CKD)

Ҳали таржима қилинмаган

Мавзулар

Atrial Fibrillation Management and Outcomes

Идентификаторлар

DOI: 10.1016/j.ekir.2022.01.341

Иқтибослар ва манбалар

0 та иқтибос0 та фойдаланилган манба

Кўрсаткичлар — AkademScholar · Тез орада